Impact of Point-Spread Function Reconstruction on 68Ga-DOTATATE PET/CT Quantitative Imaging Parameters

被引:3
|
作者
You, Helena [1 ]
Sanli, Yasemin [1 ]
Subramaniam, Rathan M. [1 ,2 ,3 ]
机构
[1] Univ Texas Southwestern Med Ctr Dallas, Dept Radiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA
[2] Univ Texas Southwestern Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA
[3] Univ Texas Southwestern Med Ctr Dallas, Harold C Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA
关键词
Ga-68-DOTATATE; neuroendocrine tumors; PET/CT; point-spread function; SOMATOSTATIN RECEPTOR SCINTIGRAPHY; TIME-OF-FLIGHT; NEUROENDOCRINE TUMORS; F-18-FDG PET/CT; MANAGEMENT; HETEROGENEITY; DIAGNOSIS; IN-111-DTPA-OCTREOTIDE; DOSIMETRY;
D O I
10.2214/AJR.18.21067
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
OBJECTIVE. The objective of our study was to investigate the impact of point-spread function (PSI) reconstruction and lesion size on Ga-68-tetraazacyclododecanetetraacetic acid-DPhel-Tyr3-octreotate (DOTATATE) PET/CT quantitative parameters. MATERIALS AND METHODS. A total of 38 patients with 42 Ga-68-DOATATE PET/CT studies and 125 lesions were included. Scans were reconstructed with and without PSF modulation. For each lesion, the maximum standardized uptake value (SUVmax) and peak standardized uptake value (SUVpeak), metabolic tumor volume (MTV), total lesion somatostatin avidity, and tumor somatostatin receptor expression heterogeneity using the AUC method were measured. Intraclass correlation coefficient (ICC) and Bland-Altman analyses were used to compare PSF and non-PSF values. A subgroup analysis was performed to determine the impact of lesion size. RESULTS. Of the 125 lesions, 51 were in the liver, 31 in lymph nodes, 17 in bone, eight in pancreas, four in lung, and 14 in other sites. The ICCs between PSF and non-PSF values were excellent for SUVmax, SUVpeak, MTV, and total lesion somatostatin avidity (ICC = 0.97-0.99), and the ICC was good for tumor somatostatin receptor expression heterogeneity (ICC = 0.81). Comparison of PSF with non-PSF values showed a bias (mean percentage change +/- SD) of 27.5% +/- 14.7% for SUVmax, 15.5% +/- 9.5% for SUVpeak, -18.6% +/- 37.6% for MTV, 0.8% +/- 28.1% for total lesion somatostatin avidity, and -7.1% +/- 11.0% for tumor somatostatin receptor expression heterogeneity. Comparison of PSF with non-PSF values for lesions less than 2 cm (n = 75) showed corresponding biases greater than those for lesions 2 cm or larger (n = 50). CONCLUSION. PSF reconstruction effected higher values for SUVmax and SUVpeak, produced decreased values for tumor somatostatin receptor expression heterogeneity, and had a variable effect on MTV and total lesion somatostatin avidity depending on lesion size.
引用
收藏
页码:683 / 688
页数:6
相关论文
共 50 条
  • [41] 68Ga-DOTATATE PET/CT in the evaluation of patients with neuroendocrine metastatic carcinoma of unknown origin
    Alonso, Omar
    Rodriguez-Taroco, Monica
    Savio, Eduardo
    Bentancourt, Cecilia
    Gambini, Juan P.
    Engler, Henry
    ANNALS OF NUCLEAR MEDICINE, 2014, 28 (07) : 638 - 645
  • [42] The Combined Interpretation of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in Metastatic Gastroenteropancreatic Neuroendocrine Tumors A Classification System With Prognostic Impact
    Hayes, Aimee R.
    O'Mahony, Luke Furtado
    Quigley, Ann-Marie
    Gnanasegaran, Gopinath
    Caplin, Martyn E.
    Navalkissoor, Shaunak
    Toumpanakis, Christos
    CLINICAL NUCLEAR MEDICINE, 2022, 47 (01) : 26 - 35
  • [43] Normal Variants, Pitfalls and Artifacts in Ga-68 DOTATATE PET/CT Imaging
    Malan, Nico
    Vangu, Mboyo-Di-Tamba
    FRONTIERS IN NUCLEAR MEDICINE, 2022, 2
  • [44] Should 68Ga-DOTATATE PET/CT be Performed Routinely in Patients with Neuroendocrine Tumors Before Surgical Resection?
    Babazadeh, Nasim T.
    Schlund, Devan J.
    Cornelius, Tyler
    Singh, Jagadeesh S.
    Tierney, John F.
    Chen, Meri
    Keutgen, Xavier M.
    WORLD JOURNAL OF SURGERY, 2020, 44 (02) : 604 - 611
  • [45] Identification and characterization of myocardial metastases in neuroendocrine tumor patients using 68Ga-DOTATATE PET-CT
    Kunz, Wolfgang G.
    Eschbach, Ralf S.
    Stahl, Robert
    Kazmierczak, Philipp M.
    Bartenstein, Peter
    Rominger, Axel
    Auernhammer, Christoph J.
    Spitzweg, Christine
    Ricke, Jens
    Cyran, Clemens C.
    CANCER IMAGING, 2018, 18
  • [46] Unusual Breast Metastasis from Atypical Lung Carcinoid on 68Ga-DOTATATE PET/CT
    Okudan, Berna
    Seven, Bedri
    Yildirim, Aslihan
    Albayrak, Aynur
    CURRENT MEDICAL IMAGING, 2024, 20
  • [47] Role of 68Ga-DOTATATE PET/TC (68Ga-PET-CT) for the Management of Patients with Neuroendrocrine Tumors (NETs): Impact in Therapeutic Decisions of our Clinical Practice
    Pesce, V
    Castillo Mandon, A.
    O'Connor, J. M.
    Bestanti, C.
    Eleta, M.
    Belli, S.
    Domenichini, E.
    Marmissolle, F.
    Kujaruk, M.
    Rosales, C.
    Paterno, M.
    Roca, E.
    NEUROENDOCRINOLOGY, 2014, 99 (3-4) : 299 - 299
  • [48] Pancreatic Perivascular Epithelioid Cell Tumor Revealed by 68Ga-DOTATATE PET/CT
    Sun, Rui
    Zeng, Guangping
    Chen, XiaoLiang
    CLINICAL NUCLEAR MEDICINE, 2023, 48 (06) : 515 - 517
  • [49] False-Positive Uptake in Splenic Hemangioma on 68Ga-DOTATATE PET/CT
    Zhu, Brian
    Yoon, Emily
    Mahajan, Sonia
    Kranz, Anca-Oana
    CLINICAL NUCLEAR MEDICINE, 2023, 48 (06) : 518 - 519
  • [50] 68Ga-DOTATATE PET/CT in recurrent medullary thyroid carcinoma: a lesion-by-lesion comparison with 111In-octreotide SPECT/CT and conventional imaging
    Itaya Yamaga, Lilian Yuri
    Cunha, Marcelo L.
    Campos Neto, Guilherme C.
    Garcia, Marcio R. T.
    Yang, Ji H.
    Camacho, Cleber P.
    Wagner, Jairo
    Funari, Marcelo B. G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (10) : 1695 - 1701